



WEDNESDAY 13th JULY 2016 COMMENCING 09:30 AM

AT [CARDIFF METROPOLITAN UNIVERSITY](#), LLANDAFF CAMPUS,
WESTERN AVENUE, CARDIFF CF5 2YB

AGENDA

- | | Enclosure |
|--|----------------------------|
| 1. Welcome and introduction | |
| 2. Apologies | |
| 3. Declarations of interest | |
| 4. Minutes of previous meeting | 1/AWMSG/0716 |
| 5. Chairman's report | |
| 6. Appraisal 1: Full Submission
Ceftolozane/tazobactam (Zerbaxa[®]) for the treatment of the following infections in adults: complicated intra-abdominal infections; acute pyelonephritis; complicated urinary tract infections. Consideration should be given to official guidance on the appropriate use of antibacterial agents | 2/AWMSG/0716
Appendices |
| 7. Appraisal 2: Limited Submission
Aprepitant (EMEND[®]) for the prevention of nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy in patients from the age of 6 months to less than 18 years old. Aprepitant is given as part of combination therapy | 3/AWMSG/0716
Appendices |

To protect commercial confidentiality the following appraisals will be held in private and the meeting will close to the public

- | | |
|---|----------------------------|
| 8. Appraisal 3: Full Submission (WPAS)
Blinatumomab (Blincyto[®]) for the treatment of adults with Philadelphia chromosome negative relapsed or refractory B-precursor acute lymphoblastic leukaemia | 4/AWMSG/0716
Appendices |
| 9. Appraisal 4: Full Submission (WPAS)
Netupitant/palonosetron (Akynzeo[®]) in adults for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cisplatin-based cancer chemotherapy and for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic cancer chemotherapy | 5/AWMSG/0716
Appendices |

10. **Appraisal 5: Full Submission (WPAS)**
Lenalidomide (Revlimid®) for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for transplant 6/AWMSG/0716
Appendices

11. **Appraisal 6: Limited Submission (WPAS)**
Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (Genvoya®) for the treatment of adults and adolescents (aged 12 years and older with body weight at least 35 kg) infected with human immunodeficiency virus 1 (HIV-1) without any known mutations associated with resistance to the integrase inhibitor class, emtricitabine or tenofovir 7/AWMSG/0716
Appendices

Date of next meeting: 21st September 2016 in Abergavenny